[
    [
        {
            "time": "",
            "original_text": "泰格医药(300347.SZ)：叶小平累计减持764.03万股 减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "叶小平",
                    "减持",
                    "764.03万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：叶小平累计减持764.03万股 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：控股股东、实际控制人减持股份数量达1% 减持股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "控股股东",
                    "实际控制人",
                    "减持",
                    "1%"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "泰格医药：控股股东、实际控制人减持股份数量达1% 减持股份",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "创新药由“中国新”变为“全球新”，4家CRO被看好",
            "features": {
                "keywords": [
                    "创新药",
                    "全球新",
                    "CRO",
                    "被看好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创新药由“中国新”变为“全球新”，4家CRO被看好",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]